Wegovy Medicare Advantage Coverage: What Women Need to Know in 2026

Does Medicare Advantage Actually Cover Wegovy?

The short answer: sometimes, and the number of plans that say yes is growing. Traditional Medicare (Parts A and B) does not cover weight-loss drugs. Part D plans were historically barred from covering obesity medications under a 1990 exclusion that predates GLP-1 drugs entirely. Medicare Advantage plans follow Part D rules for their drug benefits, so most have carried that same exclusion.

The Treat and Reduce Obesity Act has been reintroduced repeatedly in Congress, and in 2023 CMS signaled openness to covering semaglutide when prescribed for cardiovascular risk reduction. The FDA approved Wegovy for that cardiovascular indication in March 2024, based on the SELECT trial showing a 20% reduction in major adverse cardiovascular events in adults with established cardiovascular disease and a BMI of 27 or higher. That approval opened a door.

Starting in 2026, CMS finalized guidance allowing Part D plans to cover Wegovy specifically for cardiovascular risk reduction in patients who meet the SELECT trial criteria. Coverage for obesity alone, without a cardiovascular indication, remains excluded under the original Part D rule.

What That Means for You Specifically

If you have a history of heart attack, stroke, or established atherosclerotic cardiovascular disease and your BMI is 27 or above, your Medicare Advantage plan may now cover Wegovy. If you are seeking it purely for weight loss without a cardiovascular diagnosis, coverage remains much harder to obtain.

Check your Summary of Benefits and Coverage or call your plan's member services and ask: "Is semaglutide 2.4 mg (Wegovy) on your formulary for the cardiovascular risk reduction indication, and what tier is it on?" Write down the representative's name and the date.

Which Advantage Plans Are Most Likely to Cover It?

No single public list tracks this in real time. Plans that have added Wegovy for the cardiovascular indication tend to be larger national carriers (UnitedHealthcare, Humana, Aetna, BCBS-affiliated plans) offering enhanced Part D benefits in high-premium brackets. Lower-premium $0-premium plans are less likely to include it because the drug's list price is high enough to materially affect plan actuarial ratings.

The Medicare Plan Finder at medicare.gov lets you search by drug name. Enter "semaglutide" and your zip code to see which plans in your area list it and at what cost-sharing tier.

The Wegovy Prior Authorization Maze (and How to Get Through It)

Even plans that list Wegovy on formulary almost universally require prior authorization. For women, this step has some sex-specific wrinkles worth knowing.

Standard Prior Authorization Criteria

Most plans require all of the following before approving Wegovy:

• Documented cardiovascular diagnosis (for the CV indication) or obesity diagnosis with comorbidity (for plans with broader obesity coverage)
• BMI documentation, typically 30 or above, or 27 or above with a qualifying condition
• Evidence of a prior structured weight-loss attempt, often 3 to 6 months
• Prescriber attestation that lifestyle counseling is ongoing

Your clinician needs to document these in the chart before submitting. Vague notes like "patient wants to lose weight" are the single most common reason for initial denial.

Women-Specific Conditions That Strengthen Your Case

Several female-specific diagnoses can function as qualifying comorbidities that make prior authorization arguments stronger:

PCOS. Polycystic ovary syndrome affects an estimated 6 to 12% of women of reproductive age and is characterized by insulin resistance, hyperandrogenism, and difficulty with weight regulation. Semaglutide has been studied in PCOS: a 2023 trial published in the Journal of Clinical Endocrinology and Metabolism found meaningful reductions in weight and androgen levels in women with PCOS on GLP-1 agonists. Your clinician can document PCOS as a metabolic comorbidity.

Postmenopausal cardiovascular risk. Estrogen loss at menopause accelerates the accumulation of visceral adipose tissue and shifts lipid profiles toward higher LDL and triglycerides. Postmenopausal women have a steeper rise in cardiovascular risk than men of equivalent age, which can strengthen a medical-necessity argument when cardiovascular risk factors are present even before a formal atherosclerotic disease diagnosis.

Obesity-related sleep apnea, hypertension, or type 2 diabetes. These remain the most recognized qualifying comorbidities across payers. If you have any of these, they should be documented prominently in your chart and referenced explicitly in the prior authorization letter.

If You Are Denied: The Appeal Process

A denial is not final. Medicare requires plans to process standard appeals within 60 days and expedited appeals within 72 hours when delay would harm your health. The steps:

1. Request a Redetermination in writing within 60 days of the denial notice.
2. If the redetermination is upheld, request a Reconsideration by a Qualified Independent Contractor (QIC).
3. If still denied, you can escalate to an ALJ hearing and then federal court.

Realistically, step 1 and step 2 resolve most cases where the medical documentation is solid. Ask your prescriber to write a letter of medical necessity that references the SELECT trial by name, cites your specific cardiovascular risk factors, and documents prior weight-loss attempts.

What Wegovy Costs Without Coverage (and Realistic Alternatives)

The average cash price for Wegovy runs approximately $1,349 per month in 2026. Over a year, that is more than $16,000. For most women on Medicare, that is simply not sustainable.

The Novo Nordisk Savings Card

Novo Nordisk offers a savings card program that can reduce out-of-pocket costs to as low as $0 per month for commercially insured patients and $25 per month for those who qualify under specific income criteria. The important limitation: this program is explicitly for patients with commercial (private) insurance, not Medicare or Medicaid. If you are on Medicare, you are not eligible for the standard savings card.

Novo Nordisk does run a Patient Assistance Program for uninsured or underinsured patients who meet income thresholds. The application is at novocare.com and requires income verification. Processing takes several weeks.

Compounded Semaglutide: The $199 Option

When the FDA classifies a branded drug as being in shortage, compounding pharmacies may legally produce copies. Wegovy remained on and off the FDA shortage list through much of 2024 and 2025. As of 2026, the FDA has stated that the shortage has been resolved, which means compounding pharmacies are no longer supposed to produce copies of the 2.4 mg formulation for general distribution. The legal status of compounded semaglutide can shift quickly; verify with your prescriber before ordering.

When it was available, compounded semaglutide averaged around $199 per month, a fraction of the brand price. The tradeoff: compounded versions have not undergone the same FDA manufacturing scrutiny as Wegovy, and dose accuracy and sterility are not guaranteed across all compounders. The FDA issued multiple warnings about compounded semaglutide products containing incorrect doses or unapproved additives.

If you are considering a compounded option, ask your telehealth provider which 503B outsourcing facility fills the prescription. A 503B facility is held to higher standards than a traditional compounding pharmacy.

Other GLP-1 Options That May Have Better Coverage

Ozempic (semaglutide 1 mg or 2 mg) is FDA-approved for type 2 diabetes, not obesity, but Medicare Part D has historically covered it for that indication. If you have type 2 diabetes and overweight, your clinician may be able to prescribe Ozempic for the diabetes indication and you may achieve weight-related benefits. This is a medical decision that requires honest diagnosis-based prescribing, not off-label workaround prescribing. Tirzepatide (Zepbound) is a separate drug with a separate coverage pathway and is worth asking about if Wegovy hits a wall.

Pregnancy, Lactation, and Contraception: What Every Woman on Wegovy Must Know

Wegovy is contraindicated during pregnancy. Animal studies showed fetal harm at exposures below the human therapeutic dose, and there is no adequate human safety data. Novo Nordisk and the FDA recommend stopping Wegovy at least two months before attempting to conceive because of the drug's long half-life (approximately one week, meaning full washout takes several weeks).

Reproductive-Age Women: Contraception Is Non-Negotiable

If you are in your reproductive years and not planning pregnancy, use reliable contraception while taking Wegovy. Weight loss itself can restore ovulation in women who were anovulatory due to obesity or PCOS, meaning your fertility may increase precisely as you start the drug. Women who assumed they could not conceive have become pregnant on GLP-1 therapy. This is not a theoretical risk.

Wegovy may also reduce the absorption of oral contraceptives by slowing gastric emptying. The prescribing information advises that women using oral contraceptives switch to a non-oral method or add a barrier method for four weeks after each dose escalation step.

Perimenopause and Postmenopause: Lower Risk, Different Considerations

If you are postmenopausal, the pregnancy contraindication does not apply to you directly. The cardiovascular benefit data from the SELECT trial actually skewed toward older participants with established disease, which is the population most likely to be postmenopausal. Women made up about 24% of the SELECT trial population, a common under-representation that means the magnitude of benefit specifically in older women is extrapolated from a mixed-sex dataset rather than directly measured in women alone.

Lactation

There is no human data on semaglutide transfer into breast milk. Because of the molecular weight and the animal data, most clinicians advise against using Wegovy while breastfeeding. If you are in the postpartum period and breastfeeding, this is a conversation for your OB or primary care provider, not a decision to make based on internet research alone.

Who This Drug Is Right For (and Who Should Wait)

Wegovy was approved for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. That threshold is a regulatory floor, not a clinical guarantee that the drug is appropriate for every woman who meets it.

Women Who Are Strong Candidates

• Postmenopausal women with established cardiovascular disease and BMI 27 or above (strongest Medicare coverage argument)
• Women with PCOS, insulin resistance, and difficulty losing weight through lifestyle modification alone
• Women with obesity-related sleep apnea, hypertension, or type 2 diabetes who have not reached metabolic goals with existing medications
• Women who have experienced significant weight regain after bariatric surgery

Women Who Should Approach With Caution or Avoid

• Anyone currently pregnant or planning pregnancy within the next two months
• Women with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2). Wegovy carries a black box warning for thyroid C-cell tumors based on rodent data; the human risk is unknown but the contraindication stands.
• Women with a history of pancreatitis
• Women with severe gastroparesis or other serious GI motility disorders
• Women currently breastfeeding

A small but real subset of women with a history of eating disorders report that GLP-1 drugs affect their relationship with hunger in ways that are destabilizing. The suppression of appetite is not neutral for everyone. Discuss your full psychiatric and eating history with your prescriber.

How the SELECT Trial Changes the Coverage Conversation

The SELECT trial enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes. Participants received semaglutide 2.4 mg weekly or placebo. Over a mean follow-up of 33 months, the semaglutide group had a 20% lower rate of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) compared with placebo. That result held regardless of how much weight participants lost, suggesting a cardiovascular benefit partly independent of weight loss itself.

Why does this matter for Medicare coverage? Because Medicare was never barred from covering drugs for cardiovascular disease. The argument for covering Wegovy under the cardiovascular indication sidesteps the obesity exclusion entirely. Your clinician's letter of medical necessity should frame the indication as cardiovascular risk reduction in a patient meeting SELECT criteria, not as "weight loss."

The American Heart Association's 2023 scientific statement on obesity and cardiovascular disease specifically named GLP-1 receptor agonists as having a role in cardiovascular risk reduction, which gives your clinician guideline-level support for that framing.

Talking to Your Medicare Advantage Plan: A Practical Script

When you call your plan, you need specific language. A script that works:

"I am calling to ask whether semaglutide 2.4 mg, brand name Wegovy, is covered under my plan's Part D benefit for the FDA-approved cardiovascular risk reduction indication in patients with a BMI of 27 or above and established atherosclerotic cardiovascular disease. Can you tell me the formulary tier, the prior authorization criteria, and the exceptions process if I am denied?"

Document: the representative's name, the date and time, and exactly what they tell you. If they say it is not covered, ask them to mail or email you the written denial criteria so your clinician can address each one directly in a prior authorization submission.

FAQ